Recommendations and Best Practices for Reference Standards and Reagents Used in Bioanalytical Method Validation
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 2
Abstract
The continued globalization of pharmaceutics has increased the demand for companies to know and understand the regulations that exist across the globe. One hurdle facing pharmaceutical and biotechnology companies developing new drug candidates is interpreting the current regulatory guidance documents and industry publications associated with bioanalytical method validation (BMV) from each of the different agencies throughout the world. The objective of this commentary is to provide our opinions on the best practices for reference standards and key reagents, such as metabolites and internal standards used in the support of regulated bioanalysis based on a review of current regulatory guidance documents and industry white papers for BMV.
Authors and Affiliations
Joseph F. Bower, Jennifer B. McClung, Carl Watson, Takahiko Osumi, Kátia Pastre
Keywords
Related Articles
- EP ID EP681074
- DOI 10.1208/s12248-014-9566-y
- Views 66
- Downloads 0
Evaluation of an Innovative Population Pharmacokinetic-Based Design for Behavioral Pharmacodynamic Endpoints
Pre-clinical behavioral pharmacology studies supporting indications like analgesia typically consist of at least three different studies; dose-finding, duration of effect, and tolerance-development studies. Pharmacokinet...
Vesicular monoamine transporter 2: Role as a novel target for drug development
In the central nervous, system, vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release. Pharmacological...
Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects
The online version of this article (doi:10.1208/s12248-011-9302-9) contains supplementary material, which is available to authorized users.
A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adaptive Phase II Design
A potent novel compound (MK-3577) was developed for the treatment of type 2 diabetes mellitus (T2DM) through blocking the glucagon receptor. A semi-mechanistic model was developed to describe the drug effect on glucagon...
Regulator of G-protein Signaling (RGS)1 and RGS10 Proteins as Potential Drug Targets for Neuroinflammatory and Neurodegenerative Diseases
Regulator of G-protein signaling (RGS) proteins were originally identified as negative regulators of G-protein-coupled receptor (GPCR) signaling via their GTPase-accelerating protein (GAP) activity. All RGS proteins cont...